deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT05245006

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer

Sponsor: Fortis Therapeutics, Inc.

Conditions Metastatic Castration-resistant Prostate Cancer Prostate Cancer
Interventions 89Zr-DFO-YS5 Positron Emission Tomography (PET)/Computerized tomography (CT) Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) YS5 antibody
Updated 11 times since 2022 Last updated: Dec 1, 2025 Started: Mar 18, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastatic Castration-resistant Prostate Cancer and Prostate Cancer, this trial is ongoing. The trial is conducted by Fortis Therapeutics, Inc. and has accumulated 11 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshotNot Yet Recruiting~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshotRecruiting~Mar 2023 – ~Jan 2024 · 10 months · monthly snapshotRecruiting~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshotRecruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – ~Apr 2025 · 5 months · monthly snapshotRecruiting~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshotRecruiting~Jun 2025 – ~Jan 2026 · 7 months · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotActive Not Recruiting

Change History

11 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Jun 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

  3. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE1

  4. Nov 2024 — Apr 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1

▶ Show 6 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  3. Jan 2024 — Jun 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  5. Apr 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  6. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fortis Therapeutics, Inc.
  • Robert Flavell, MD, PhD
  • United States Department of Defense
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations